BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20709477)

  • 21. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
    Susce MT; Murray-Carmichael E; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
    Sistonen J; Madadi P; Ross CJ; Yazdanpanah M; Lee JW; Landsmeer ML; Nauta M; Carleton BC; Koren G; Hayden MR
    Clin Pharmacol Ther; 2012 Apr; 91(4):692-9. PubMed ID: 22398969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacogenetics of analgesia.
    Stamer UM; Stüber F
    Expert Opin Pharmacother; 2007 Oct; 8(14):2235-45. PubMed ID: 17927480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical application of pharmacogenetics in pain management.
    Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
    Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
    Adegbola MA
    Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suspected opioid overdose case resolved by CYP2D6 genotyping.
    Shaw KD; Amstutz U; Jimenez-Mendez R; Ross CJ; Carleton BC
    Ther Drug Monit; 2012 Apr; 34(2):121-3. PubMed ID: 22406651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genetics, pain and analgesia].
    Stamer U; Bayerer B; Stüber F
    Anaesthesist; 2006 Jul; 55(7):746-52. PubMed ID: 16625360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.
    Zwisler ST; Enggaard TP; Noehr-Jensen L; Mikkelsen S; Verstuyft C; Becquemont L; Sindrup SH; Brosen K
    Fundam Clin Pharmacol; 2010 Aug; 24(4):517-24. PubMed ID: 19845769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics in breast cancer therapy.
    Tan SH; Lee SC; Goh BC; Wong J
    Clin Cancer Res; 2008 Dec; 14(24):8027-41. PubMed ID: 19088019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
    Owusu Obeng A; Hamadeh I; Smith M
    Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence Regarding Pharmacogenetics in Pain Management and Cancer.
    Smith DM; Figg WD
    Oncologist; 2023 Mar; 28(3):189-192. PubMed ID: 36718020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pain polymorphisms and opioids: An evidence based review.
    Vieira CMP; Fragoso RM; Pereira D; Medeiros R
    Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen pharmacogenetics moves closer to reality.
    Garber K
    J Natl Cancer Inst; 2005 Mar; 97(6):412-3. PubMed ID: 15770000
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
    Naito T; Kawakami J
    Yakugaku Zasshi; 2015; 135(5):709-15. PubMed ID: 25948306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genetic polymorphisms and opioid therapies].
    Landau R
    Presse Med; 2008 Oct; 37(10):1415-22. PubMed ID: 18440763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.
    Rakvåg TT; Klepstad P; Baar C; Kvam TM; Dale O; Kaasa S; Krokan HE; Skorpen F
    Pain; 2005 Jul; 116(1-2):73-8. PubMed ID: 15927391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
    Kiyotani K; Mushiroda T; Hosono N; Tsunoda T; Kubo M; Aki F; Okazaki Y; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2010 Sep; 20(9):565-8. PubMed ID: 20574415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.